Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunovia AB ( (SE:IMMNOV) ) has provided an announcement.
Immunovia announced the publication of its CLARITI clinical study in the journal Gastroenterology, highlighting the PancreaSure test’s ability to detect early-stage pancreatic cancer with high sensitivity and specificity. This publication validates the test’s diagnostic potential and strengthens Immunovia’s position in the pancreatic cancer diagnostics industry, potentially benefiting stakeholders by enhancing early detection capabilities.
More about Immunovia AB
Immunovia AB is a diagnostic company listed on Nasdaq Stockholm, specializing in early detection of pancreatic cancer through simple blood-based testing. The company collaborates with healthcare providers, experts, and advocacy groups to make its tests available to high-risk individuals, with a significant market focus in the USA.
YTD Price Performance: -23.35%
Average Trading Volume: 14,295,184
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK208M
For an in-depth examination of IMMNOV stock, go to TipRanks’ Overview page.